Ocugen, Inc. Announces $20 Million Registered Direct Offering of Common Stock and Warrants
MALVERN, Pa., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced th...
How does this offering compare to recent capital‑raising activities by peer biotech companies in terms of size, pricing, and warrant structures?
Are there any covenants or lock‑up periods associated with the securities purchase agreement that could affect future share sales or insider activity?
What is the likely impact on the stock’s liquidity and bid‑ask spread once the offering is completed?
Symbol:
OCGN
30 days ago